RxDoctor Payments Data

Julia Chaw Chih Lee

Family · Los Angeles, CANPI 1891899456

Payments from drug & device makers

$3,250in general payments, 2019–2025

Across 61 payments — averaging $53.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$471
  • Novo Nordisk$446
  • GSK$303
  • Gilead$244
  • AbbVie$212
  • Bayer$181
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$3,250100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,250 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.

See all family providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin62$84,681
RybelsusSemaglutide22$47,001
ProliaDenosumab17$27,064
FarxigaDapagliflozin Propanediol21$26,871
VascepaIcosapent Ethyl38$23,763
JanuviaSitagliptin Phosphate16$16,575
TradjentaLinagliptin12$13,478
ArexvyRsvpref3 Antigen/As01e/Pf29$8,082
DapagliflozinDapagliflozin Propanediol13$6,374
Icosapent Ethyl18$3,435
Omega-3 Acid Ethyl Esters18$1,687
Atorvastatin Calcium234$1,428
Rosuvastatin Calcium81$1,369
Losartan Potassium145$1,020
Amlodipine Besylate186$996

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus$446$47,00122 claims
AmgenProlia$471$27,06417 claims
AstraZenecaFarxiga$125$26,87121 claims
MerckJanuvia$24$16,57516 claims
GSKArexvy$303$8,08229 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.

Other family in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →